The Michael J. Fox Foundation
Industry Partners
Biotechnology and pharmaceutical companies play a key role in the Foundation’ s roadmap strategy to accelerate improved treatments for Parkinson’ s disease. Their support expands our capability to speed clinical trials, engage the Parkinson’ s community in research, and bring science closer to a cure. Collectively, these partners contributed more than $ 5 million to our programs in 2017.
We also extend our gratitude to the 2017 Parkinson’ s Disease Education Consortium. This alliance of industry partners supports our commitment to furnishing high-quality educational resources for the PD community while preserving our track record of efficiency in stewarding donor-raised contributions for maximum impact on Parkinson’ s drug development.
Learn more at michaeljfox. org / sponsors.
Abbvie
Acadia Pharmaceuticals *
Acorda Therapeutics
Adamas Pharmaceuticals *
Allergan Amgen Amicus Therapeutics
BIO( Biotechnology Innovation Organization)
Biogen
Bristol Meyers Squibb
Cellular Dynamics International *
Charles River Laboratories
GlaxoSmithKline Impax Laboratories
Institut de Recherches Internationales Servier
Lundbeck *
Medical Device Innovation Consortium( MDIC)
Merck and Co
Meso Scale Diagnostics
Pfizer *
Prothena Biosciences *
Regeneron Pharmaceuticals
Sunovion Pharmaceuticals *
Takeda Pharmaceuticals International
UCB United Technologies Voyager Therapeutics
* Parkinson’ s Disease Education Consortium
18